← Back to headlines
SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy
SCYNEXIS, Inc. (SCYX) has announced that the first participants have been dosed in its Phase 1 trial for SCY-247, an antifungal therapy.
12 Mar, 07:38 — 12 Mar, 07:38
Sources
Showing 1 of 1 sources
